Bacterial endophthalmitis is an ocular inflammation caused by the introduction of an infectious agent into the posterior segment of the eye following intraocular surgery, penetrating eye injury, or via blood borne spread from a distant anatomical site. Although rare, the complications stemming from endophthalmitis can be catastrophic as irreversible damage to the retina frequently occurs during infection, and often results in visual loss.

Glaucoma is a group of conditions that can damage the eye's optic nerve, if left untreated it can cause vision loss and blindness. Glaucoma is usually associated with elevated pressure in the eye (intraocular pressure, IOP), which can lead to damage of the optic nerve. IOP build-up is usually caused by an increased production of aqueous humour or due to the improper functioning of the drainage system that facilitates outward filtration. The disease can strike at any age, but is most common in those over 60 years.

Osteoarthritis (OA) is a degenerative disease characterised by loss of cartilage, joint pain and disability. OA is one of the most common forms of arthritis and is a leading cause of disability globally. OA can affect any joint of the body including the knee, hips, spine and finger joints, but most commonly the knees and hips. The causes of osteoarthritis in the knee and cartilage breakdown include age-related degeneration of knee cartilage and surgery-related changes in anatomy of the knee joint following knee procedures.

PolyActiva's drug-polymer conjugate technology represent a significant advance on current technology, it enables site specific delivery of drugs directly to the affected area.

The key attributes include controlled rate of drug release, high drug loading, complete bio-erosion to non-toxic products, and a polymer conjugate which enables to fine tuning of physical, functional and PK properties.

The size of the implants may vary depending on the application. Polymer can be processed as rods, films, or fiber coated form. For example for the treatment of glaucoma, the implants are in the form of rods designed to fit into the lumen of a syringe needle. PolyActiva can currently prepare rod implants of different lengths and in diameters ranging from 0.2 mm to 2.5 mm.

Once the drug is released, the polymer completely bio-erodes into non-toxic harmless byproducts, such as amino acids, which get cleared from the site of action, leaving behind no residue.

Couldn't find what you were looking for?

Please submit the form below or contact us.